BACKGROUND: EGFR T790M is the most common mutation associated with acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Baseline EGFR T790M mutations in EGFR TKI-naïve patients have been reported, but the frequency and their association with response to EGFR TKIs remain unclear. PATIENTS AND METHODS: The frequency of baseline EGFR T790M as detected by routine molecular genotyping was determined by reviewing clinical results obtained at our institution from 2009 to 2013. We also collected outcome data for treatment with EGFR TKIs. RESULTS: To define the incidence of EGFR T790M, we reviewed 2774 sequentially tested patients with lung cancer who underwent molecular testing using a mass spectrometry-based assay, and 11 (0.5%) had baseline EGFR T790M. Compiling results from several molecular techniques, we observed EGFR T790M in tumors from 20 patients who had not previously been treated with an EGFR TKI. In all cases, EGFR T790M occurred concurrently with another EGFR mutation, L858R (80%, 16/20), or exon 19 deletion (20%, 4/20). Two percent of all pre-treatment EGFR-mutant lung cancers harbored an EGFR T790M mutation. Thirteen patients received erlotinib monotherapy as treatment for metastatic disease. The response rate was 8% (1/13, 95% confidence interval 0%-35%). For the patients who received erlotinib, the median progression-free survival was 2 months and the median overall survival was 16 months. CONCLUSIONS: De novo EGFR T790M mutations are rare (<1%) when identified by standard sensitivity methods. TKI therapy for patients with baseline EGFR T790M detected by standard molecular analysis has limited benefit.
BACKGROUND:EGFRT790M is the most common mutation associated with acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Baseline EGFRT790M mutations in EGFR TKI-naïve patients have been reported, but the frequency and their association with response to EGFR TKIs remain unclear. PATIENTS AND METHODS: The frequency of baseline EGFRT790M as detected by routine molecular genotyping was determined by reviewing clinical results obtained at our institution from 2009 to 2013. We also collected outcome data for treatment with EGFR TKIs. RESULTS: To define the incidence of EGFRT790M, we reviewed 2774 sequentially tested patients with lung cancer who underwent molecular testing using a mass spectrometry-based assay, and 11 (0.5%) had baseline EGFRT790M. Compiling results from several molecular techniques, we observed EGFRT790M in tumors from 20 patients who had not previously been treated with an EGFR TKI. In all cases, EGFRT790M occurred concurrently with another EGFR mutation, L858R (80%, 16/20), or exon 19 deletion (20%, 4/20). Two percent of all pre-treatment EGFR-mutant lung cancers harbored an EGFRT790M mutation. Thirteen patients received erlotinib monotherapy as treatment for metastatic disease. The response rate was 8% (1/13, 95% confidence interval 0%-35%). For the patients who received erlotinib, the median progression-free survival was 2 months and the median overall survival was 16 months. CONCLUSIONS: De novo EGFRT790M mutations are rare (<1%) when identified by standard sensitivity methods. TKI therapy for patients with baseline EGFRT790M detected by standard molecular analysis has limited benefit.
Authors: Daphne W Bell; Ira Gore; Ross A Okimoto; Nadia Godin-Heymann; Raffaella Sordella; Roseann Mulloy; Sreenath V Sharma; Brian W Brannigan; Gayatry Mohapatra; Jeff Settleman; Daniel A Haber Journal: Nat Genet Date: 2005-10-30 Impact factor: 38.330
Authors: Lecia V Sequist; Renato G Martins; David Spigel; Steven M Grunberg; Alexander Spira; Pasi A Jänne; Victoria A Joshi; David McCollum; Tracey L Evans; Alona Muzikansky; Georgiana L Kuhlmann; Moon Han; Jonathan S Goldberg; Jeffrey Settleman; A John Iafrate; Jeffrey A Engelman; Daniel A Haber; Bruce E Johnson; Thomas J Lynch Journal: J Clin Oncol Date: 2008-05-05 Impact factor: 44.544
Authors: Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: Laura E MacConaill; Elizabeth Garcia; Priyanka Shivdasani; Matthew Ducar; Ravali Adusumilli; Marc Breneiser; Mark Byrne; Lawrence Chung; Jodie Conneely; Lauren Crosby; Levi A Garraway; Xin Gong; William C Hahn; Charlie Hatton; Philip W Kantoff; Michael Kluk; Frank Kuo; Yonghui Jia; Ruchi Joshi; Janina Longtine; Allison Manning; Emanuele Palescandolo; Nematullah Sharaf; Lynette Sholl; Paul van Hummelen; Jacqueline Wade; Bruce M Wollinson; Dimity Zepf; Barrett J Rollins; Neal I Lindeman Journal: J Mol Diagn Date: 2014-08-23 Impact factor: 5.568
Authors: Stephen R Fairclough; Lesli A Kiedrowski; Jessica J Lin; Ori Zelichov; Gabi Tarcic; Thomas E Stinchcombe; Justin I Odegaard; Richard B Lanman; Alice T Shaw; Rebecca J Nagy Journal: Exp Hematol Oncol Date: 2019-10-11
Authors: Yang Yang; Yi Meng; Hang Zhang; Xiaoyan Shen; Rutian Li; Lixia Yu; Baorui Liu; Lifeng Wang Journal: Oncol Lett Date: 2017-12-19 Impact factor: 2.967
Authors: M Cabanero; R Sangha; B S Sheffield; M Sukhai; M Pakkal; S Kamel-Reid; A Karsan; D Ionescu; R A Juergens; C Butts; M S Tsao Journal: Curr Oncol Date: 2017-04-27 Impact factor: 3.677
Authors: Kenichi Suda; Paul A Bunn; Christopher J Rivard; Tetsuya Mitsudomi; Fred R Hirsch Journal: J Thorac Oncol Date: 2016-09-15 Impact factor: 15.609
Authors: David F Heigener; Christian Schumann; Martin Sebastian; Parvis Sadjadian; Ingo Stehle; Angela Märten; Anne Lüers; Frank Griesinger; Matthias Scheffler Journal: Oncologist Date: 2015-09-09
Authors: Helena A Yu; Ken Suzawa; Emmet Jordan; Ahmet Zehir; Ai Ni; Ryan Kim; Mark G Kris; Matthew D Hellmann; Bob T Li; Romel Somwar; David B Solit; Michael F Berger; Maria Arcila; Gregory J Riely; Marc Ladanyi Journal: Clin Cancer Res Date: 2018-03-12 Impact factor: 12.531